CRLBF
Price
$0.89
Change
-$0.05 (-5.32%)
Updated
Feb 21 closing price
Capitalization
501.04M
18 days until earnings call
GTBIF
Price
$7.11
Change
+$0.12 (+1.72%)
Updated
Feb 21 closing price
Capitalization
1.68B
Ad is loading...

CRLBF vs GTBIF

Header iconCRLBF vs GTBIF Comparison
Open Charts CRLBF vs GTBIFBanner chart's image
Cresco Labs
Price$0.89
Change-$0.05 (-5.32%)
Volume$216.3K
Capitalization501.04M
Green Thumb Industries
Price$7.11
Change+$0.12 (+1.72%)
Volume$259.07K
Capitalization1.68B
CRLBF vs GTBIF Comparison Chart
Loading...
CRLBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GTBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRLBF vs. GTBIF commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRLBF is a Hold and GTBIF is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (CRLBF: $0.89 vs. GTBIF: $7.11)
Brand notoriety: CRLBF and GTBIF are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: CRLBF: 32% vs. GTBIF: 57%
Market capitalization -- CRLBF: $501.04M vs. GTBIF: $1.68B
CRLBF [@Pharmaceuticals: Other] is valued at $501.04M. GTBIF’s [@Pharmaceuticals: Other] market capitalization is $1.68B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.61B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRLBF’s FA Score shows that 0 FA rating(s) are green whileGTBIF’s FA Score has 0 green FA rating(s).

  • CRLBF’s FA Score: 0 green, 5 red.
  • GTBIF’s FA Score: 0 green, 5 red.
According to our system of comparison, both CRLBF and GTBIF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRLBF’s TA Score shows that 3 TA indicator(s) are bullish while GTBIF’s TA Score has 5 bullish TA indicator(s).

  • CRLBF’s TA Score: 3 bullish, 7 bearish.
  • GTBIF’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, GTBIF is a better buy in the short-term than CRLBF.

Price Growth

CRLBF (@Pharmaceuticals: Other) experienced а -5.26% price change this week, while GTBIF (@Pharmaceuticals: Other) price change was -1.25% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.14%. For the same industry, the average monthly price growth was +77.04%, and the average quarterly price growth was +50.35%.

Reported Earning Dates

CRLBF is expected to report earnings on May 14, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-1.14% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GTBIF($1.68B) has a higher market cap than CRLBF($501M). CRLBF YTD gains are higher at: -2.586 vs. GTBIF (-12.974). GTBIF has higher annual earnings (EBITDA): 253M vs. CRLBF (-16.73M). GTBIF has more cash in the bank: 185M vs. CRLBF (88.8M). GTBIF has less debt than CRLBF: GTBIF (541M) vs CRLBF (678M). GTBIF has higher revenues than CRLBF: GTBIF (1.02B) vs CRLBF (822M).
CRLBFGTBIFCRLBF / GTBIF
Capitalization501M1.68B30%
EBITDA-16.73M253M-7%
Gain YTD-2.586-12.97420%
P/E RatioN/A172.41-
Revenue822M1.02B80%
Total Cash88.8M185M48%
Total Debt678M541M125%
FUNDAMENTALS RATINGS
CRLBF vs GTBIF: Fundamental Ratings
CRLBF
GTBIF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9384
PRICE GROWTH RATING
1..100
6584
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GTBIF's Valuation (63) in the null industry is in the same range as CRLBF (73). This means that GTBIF’s stock grew similarly to CRLBF’s over the last 12 months.

GTBIF's Profit vs Risk Rating (100) in the null industry is in the same range as CRLBF (100). This means that GTBIF’s stock grew similarly to CRLBF’s over the last 12 months.

GTBIF's SMR Rating (84) in the null industry is in the same range as CRLBF (93). This means that GTBIF’s stock grew similarly to CRLBF’s over the last 12 months.

CRLBF's Price Growth Rating (65) in the null industry is in the same range as GTBIF (84). This means that CRLBF’s stock grew similarly to GTBIF’s over the last 12 months.

GTBIF's P/E Growth Rating (98) in the null industry is in the same range as CRLBF (100). This means that GTBIF’s stock grew similarly to CRLBF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRLBFGTBIF
RSI
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 5 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
81%
MACD
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 6 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
79%
Aroon
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
84%
View a ticker or compare two or three
Ad is loading...
CRLBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GTBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARCT17.770.85
+5.02%
Arcturus Therapeutics Holdings
MSFT408.21-7.92
-1.90%
Microsoft Corp
ERO12.81-0.80
-5.88%
Ero Copper Corp
OSK103.17-7.13
-6.46%
Oshkosh Corp
WLGS4.91-0.61
-11.05%
Wang & Lee Group

CRLBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRLBF has been closely correlated with TSNDF. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRLBF jumps, then TSNDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRLBF
1D Price
Change %
CRLBF100%
-5.31%
TSNDF - CRLBF
76%
Closely correlated
-2.58%
CURLF - CRLBF
76%
Closely correlated
-0.70%
TCNNF - CRLBF
75%
Closely correlated
+0.23%
JUSHF - CRLBF
74%
Closely correlated
+3.70%
VRNOF - CRLBF
73%
Closely correlated
N/A
More